Loading
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Regular session
$2.54
$0.00 · -1.53%
Regular session · ET · Market data may be delayed.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Day range
Current $2.54
52-week range
Current $2.54
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
42
Mixed
Risk
66
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Day range
Current $2.54
52-week range
Current $2.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 7.68M USD | 3.71M USD | 1.16M USD | — | — |
| Cost of goods sold | 7.43M USD | 5.37M USD | 2.47M USD | 555K USD | — |
| Gross profit | 252K USD | −1.66M USD | −1.31M USD | −555K USD | — |
| Research and development | 10.24M USD | 16.86M USD | 24.36M USD | 16.81M USD | 11.8M USD |
| Selling, general, and administrative | 19.06M USD | 26.02M USD | 37.34M USD | 34.69M USD | 18.91M USD |
| Operating expenses | 29.3M USD | 42.87M USD | 61.7M USD | 51.5M USD | 40.71M USD |
| Interest expense | — | 3.02M USD | 2.91M USD | 30K USD | 775K USD |
| Depreciation and amortization | 3.65M USD | 3.57M USD | 2.35M USD | 1.17M USD | 588K USD |
| Operating income | −29.04M USD | −44.54M USD | −63.01M USD | −52.06M USD | −40.71M USD |
| Net income | −33.25M USD | −46.63M USD | −60.24M USD | −55.82M USD | −43.18M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
293.70% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
